Company Filing History:
Years Active: 2004
Title: Per Olaf Gunnar Arkhammer: Innovator in Bioactive Molecule Screening
Introduction
Per Olaf Gunnar Arkhammer is a distinguished inventor located in Helsingborg, Sweden. He has made significant contributions to the field of bioactive molecule screening with his innovative approach and patented technology. His work is particularly notable at Bioimage A/S, a company focused on advancing scientific methods in the biopharmaceutical industry.
Latest Patents
Arkhammer holds a patent for a "Method and apparatus for high density format screening for bioactive molecules." This invention introduces a method and apparatus that allows the screening of an array of test compounds for bioactivity. The process involves contacting the test compounds with a detector layer that is capable of detecting bioactivity, composed of physiologically viable cells. This method effectively facilitates the simultaneous assay of a large number of compounds in parallel, eliminating the need for complex fluidic devices, thus streamlining research processes.
Career Highlights
Throughout his career, Arkhammer has positioned himself as a key innovator within the biotechnology sector. His role at Bioimage A/S has allowed him to apply his expertise in creating solutions that respond to critical challenges in bioactivity testing, making significant strides in research methodologies that can influence drug development and screening.
Collaborations
Throughout his professional journey, Arkhammer has collaborated with various esteemed colleagues, including Bernard Robert Terry and Kurt Scudder. These collaborations have further enriched his work and contributed to the development of innovative solutions in the field of bioactive testing.
Conclusion
Per Olaf Gunnar Arkhammer is a prominent figure in the realm of biotechnology, recognized for his innovative contributions to high density format screening for bioactive molecules. His patent reflects his commitment to enhancing bioactivity testing methodologies, and his role at Bioimage A/S continues to shape the future of scientific research in this vital area.